Biogen (FRA:IDP) Additional Paid-In Capital : €303 Mil(As of Mar. 2024)

View and export this data going back to . Start your Free Trial

What is Biogen Additional Paid-In Capital?

Biogen's quarterly additional paid-in capital increased from Sep. 2023 (€227 Mil) to Dec. 2023 (€277 Mil) and increased from Dec. 2023 (€277 Mil) to Mar. 2024 (€303 Mil).

Biogen's annual additional paid-in capital increased from Dec. 2021 (€60 Mil) to Dec. 2022 (€69 Mil) and increased from Dec. 2022 (€69 Mil) to Dec. 2023 (€277 Mil).

Biogen Additional Paid-In Capital Historical Data

The historical data trend for Biogen's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biogen Additional Paid-In Capital Chart

Biogen Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Additional Paid-In Capital

Get a 7-Day Free Trial

60.36

69.20

277.39

Biogen Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Additional Paid-In Capital	Get a 7-Day Free Trial															85.18	157.56	226.94	277.39	303.14

Biogen Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital

(Issue Price

Par Value)

Shares Outstanding (Diluted Average)

Biogen Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of Biogen's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Biogen (FRA:IDP) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Biogen Inc (FRA:IDP) » Definitions » Additional Paid-In Capital

Comparable Companies

Traded in Other Exchanges

BIIB:USA BIIB:Mexico 1BIIB:Italy IDP:Germany BIIB34:Brazil BIIB:Austria BIIB:Argentina

Address

225 Binney Street, Cambridge, MA, USA, 02142

Website

https://www.biogen.com

Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel multiple sclerosis drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is copromoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with Sobi) were spun off as part of Bioverativ in 2017. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (post-partum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology-related fields.

Biogen (FRA:IDP) Headlines

No Headlines